- Home
- MDWD vs RGC Comparison
MDWD vs RGC Comparison
Compare MDWD & RGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDWD
- RGC
- Stock Information
- Founded
- MDWD 2000
- RGC 2014
- Country
- MDWD Israel
- RGC Hong Kong
- Employees
- MDWD N/A
- RGC N/A
- Industry
- MDWD Medicinal Chemicals and Botanical Products
- RGC Medicinal Chemicals and Botanical Products
- Sector
- MDWD Health Care
- RGC Health Care
- Exchange
- MDWD Nasdaq
- RGC Nasdaq
- Market Cap
- MDWD 179.1M
- RGC 171.1M
- IPO Year
- MDWD 2014
- RGC 2021
- Fundamental
- Price
- MDWD $18.06
- RGC $5.66
- Analyst Decision
- MDWD Strong Buy
- RGC
- Analyst Count
- MDWD 1
- RGC 0
- Target Price
- MDWD $28.00
- RGC N/A
- AVG Volume (30 Days)
- MDWD 52.9K
- RGC 28.0K
- Earning Date
- MDWD 08-14-2024
- RGC 10-25-2024
- Dividend Yield
- MDWD N/A
- RGC N/A
- EPS Growth
- MDWD N/A
- RGC N/A
- EPS
- MDWD N/A
- RGC N/A
- Revenue
- MDWD $20,141,000.00
- RGC N/A
- Revenue This Year
- MDWD $30.16
- RGC N/A
- Revenue Next Year
- MDWD $18.44
- RGC N/A
- P/E Ratio
- MDWD N/A
- RGC N/A
- Revenue Growth
- MDWD N/A
- RGC N/A
- 52 Week Low
- MDWD $7.45
- RGC $3.03
- 52 Week High
- MDWD $24.00
- RGC $32.44
- Technical
- Relative Strength Index (RSI)
- MDWD 51.78
- RGC 40.22
- Support Level
- MDWD $16.25
- RGC $5.05
- Resistance Level
- MDWD $17.90
- RGC $6.57
- Average True Range (ATR)
- MDWD 1.02
- RGC 0.74
- MACD
- MDWD 0.00
- RGC -0.25
- Stochastic Oscillator
- MDWD 42.09
- RGC 16.85
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.